Should be plenty of time if they truly are prepared to solely focus on their trials. Based on recent events it does seem that is the case. We knew the company has been conducting a strategic review of their clinical programs but I guess the one thing I got from that interview is it sounds like we should be getting an update on that review in the next few weeks. Hopefully it impresses.
News 
Market Data 
Discover 
